Carisma Therapeutics raised nearly $60M in Series A funding. Now what? - Technical.ly Philly

Business

Aug. 8, 2019 10:42 am

Carisma Therapeutics raised nearly $60M in Series A funding. Now what?

What's ahead for the cell therapy startup working out of the now-full BioLabs@CIC.
Lab space at BioLabs@CIC.

Lab space at BioLabs@CIC.

(Photo by Julie Zeglen)

Carisma Therapeutics, working on a cellular therapy aimed at fighting solid tumors, is planning for growth: The University City company is hoping to hire about 10 more employees by the end of the year after raising nearly $60 million, its CEO told Techncial.ly Philly.

The company, formerly known as CARMA Therapeutics, initially raised $53 million during its Series A round last year, partly through the University of Pennsylvania, although the institution didn’t share how much it contributed.

But Carisma picked up a few million more at the end of last year, CEO Steven Kelly said. The company extended its Series A, bringing in about $6 million more, led by AbbVie Ventures and HealthCap. The funding will be put toward “full research and development capabilities,” Kelly said, as well as hiring to reach about 30 employees total.

Carisma was the first to occupy space in the BioLabs@CIC shortly after it opened in December 2018 after previously working out of the Princeton BioLabs. It was touted as a darling of the lab space during a May reception at BioLabs@CIC, with Kelly providing some remarks about Philly’s attractiveness for growing a life sciences company (an opinion that falls in line with recent international recognition).

(Photo by Julie Zeglen)

Melina Blees speaks a BioLabs reception, May 2019.

Melina Blees, the site director of the BioLabs@CIC, said all lab spaces are now all occupied by biolife companies, alongside a healthy waiting list. Companies can choose either private or shared lab space.

Advertisement

“In many ways we’re competitive,” the Boston-bred Kelly told Technical.ly about working around other companies that are often striving for the same goals, “and in other ways we’re collaborative.”

The CEO said as the team grows, it will eventually look into getting its own space.

“For now, the facility is full. All the labs are taken,” he said. “That feels great as a biotech entrepreneur, to feel the energy around biotech and cell and gene therapy — that feels great.”

Blees agreed, saying that the space filling quickly with innovative companies has helped build the biotech and biolife community in Philly.

“It’s been really crazy, even faster than we anticipated,” she said. “It speaks to how the market is really ready for these offerings.”

-30-
CONTRIBUTE TO THE
JOURNALISM FUND

Already a contributor? Sign in here
Connect with companies from the Technical.ly community
New call-to-action

Advertisement

A cell and gene therapy development center is taking 680K square feet at KOP’s Discovery Labs

A new Philly nonprofit connects life science pros to poverty-fighting volunteer opportunities

Philly saw $1.35B in business deals in 2019, with life sciences leading

SPONSORED

Philly

How the history of Linode HQ inspires its employees

Chesterbrook, PA

Deacom

Software Consulting Specialist

Apply Now

1217 Sansom Street, Philadelphia, PA 19107

Perpay

Performance Marketer

Apply Now

Chesterbrook, PA

Deacom

Software Implementation Consultant

Apply Now

This rising Philly-made startup is shutting down. Here’s why, in its founder’s words

Philadelphia prayed for a tech unicorn with a household name. Now what?

Here’s what we know about goPuff’s reported $750M SoftBank investment

SPONSORED

Philly

When it comes to diversity, Vanguard puts its money where its mouth is

Philadelphia, PA

Vistar Media

Software Engineer

Apply Now

Philadelphia area

Chariot Solutions

Mobile Developers

Apply Now

1217 Sansom Street, Philadelphia, PA

Perpay

Director of Marketing

Apply Now

Sign-up for daily news updates from Technical.ly Philadelphia

Do NOT follow this link or you will be banned from the site!